Diversify Advisory Services LLC Sells 3,043 Shares of AstraZeneca PLC $AZN

Diversify Advisory Services LLC lowered its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 12.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 20,762 shares of the company’s stock after selling 3,043 shares during the quarter. Diversify Advisory Services LLC’s holdings in AstraZeneca were worth $1,697,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC lifted its stake in shares of AstraZeneca by 93.2% in the 4th quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock valued at $379,000 after purchasing an additional 2,789 shares during the period. AQR Capital Management LLC lifted its position in AstraZeneca by 45.3% during the first quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock valued at $2,756,000 after buying an additional 11,690 shares during the period. Wedbush Securities Inc. lifted its position in AstraZeneca by 5.7% during the second quarter. Wedbush Securities Inc. now owns 8,627 shares of the company’s stock valued at $603,000 after buying an additional 462 shares during the period. AE Wealth Management LLC boosted its holdings in shares of AstraZeneca by 11.7% during the 2nd quarter. AE Wealth Management LLC now owns 10,810 shares of the company’s stock valued at $755,000 after buying an additional 1,129 shares in the last quarter. Finally, Summit Investment Advisors Inc. grew its position in shares of AstraZeneca by 2.8% in the 1st quarter. Summit Investment Advisors Inc. now owns 19,048 shares of the company’s stock worth $1,400,000 after buying an additional 522 shares during the period. 20.35% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on AZN shares. HSBC reiterated a “buy” rating and issued a $108.00 price target on shares of AstraZeneca in a research note on Wednesday, December 10th. Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday, January 21st. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of AstraZeneca in a report on Friday, February 6th. Barclays reissued an “overweight” rating on shares of AstraZeneca in a research report on Tuesday, January 6th. Finally, Citigroup began coverage on AstraZeneca in a research note on Tuesday, January 27th. They issued a “buy” rating on the stock. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, AstraZeneca currently has a consensus rating of “Moderate Buy” and an average target price of $95.75.

AstraZeneca Stock Performance

Shares of AZN stock opened at $195.08 on Wednesday. The company has a market capitalization of $302.56 billion, a price-to-earnings ratio of 64.81, a price-to-earnings-growth ratio of 1.59 and a beta of 0.32. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.69 and a current ratio of 0.88. AstraZeneca PLC has a one year low of $122.48 and a one year high of $212.71. The company’s 50-day moving average is $150.81 and its 200 day moving average is $108.23.

AstraZeneca Dividend Announcement

The business also recently announced a dividend, which will be paid on Monday, March 23rd. Shareholders of record on Friday, February 20th will be paid a dividend of $1.595 per share. The ex-dividend date is Friday, February 20th. This represents a yield of 156.0%. AstraZeneca’s dividend payout ratio is currently 66.26%.

AstraZeneca Company Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.